DnB Markets - ALK-abello A/S Class B (ALK B) ALK-Abello (Hold, TP: DKK2050.00) - Strong underlying growth outlook

Report

DnB Markets

Jesper Ingildsen

EUR 93.28 For Business Accounts Only

ALK-Abello (Hold, TP: DKK2050.00) - Strong underlying growth outlook

ALK-Abello (ALKB DC, Hold) - Strong underlying growth outlook (16 pages)

06/02/2020 16 EN

Underlying

ALK-abello A/S Class B

Alk-Abello is engaged in the development and marketing of pharmaceutical products for the treatment, prevention and diagnosis of allergies. Co.'s product portfolio comprises allergy vaccines, emergency treatments and allergy diagnostics products. Co.'s allergy vaccines product offering comprises tablet vaccines, sublingual vaccines and subcutaneous vaccines. Co.'s emergency treatments product offering comprises products for the management of anaphylaxis. Co.'s allergy diagnostics product offering comprises allergen extracts for allergy testing, such as skin-prick tests.

See profile

DK0060027142 Nasdaq Nordic Copenhagen Denmark

Provider

DnB Markets

DNB Markets is the investment banking arm of DNB Bank ASA and is focused primarily on the Nordic region, as well as internationally on niches such as global shipping, energy and related services, and seafood. DNB Markets offers services in FICC, Equities and Investment Banking advisory from offices in Oslo, Stockholm, London, Singapore and New York. Equity research coverage is offered on c250 Nordic companies. DNB was ranked no.2 in Extel Nordic Research 2017. The DNB Markets’ Credit and FICC Macro & FX Research teams are repeatedly highly rated by Prospera Nordic Institutional Investor Surveys.

See profile

Analysts

Jesper Ingildsen

Other Reports on these Companies

SmartInsider

Alk-Abello A S: 1 director

A director at Alk-Abello A S bought 1,880 shares at 132.600DKK and the significance rating of the trade was 53/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names of boa...

Free Trial

March 7, 2024 March 7, 2024 1 EN

DnB Markets

ALK-Abello (Buy, TP: DKK140.00) - Q3 rebound was not a one-off

While the Q4 results were fairly in line, sales growth for the important European tablets was stronger than expected, showing the rebound in Q3 was not a one-off. In addition, the 2024 guidance notably suggests organic growth returning to >10% and still-strong margin expansion, while the CMD in Q2 is likely to reconfirm the 2025 EBIT margin target. We reiterate our BUY and have raised our target price to DKK140 (127). European tablet momentum still strong. Q4 organic growth of c10% was largely in line with expectations (consensus 9.7%), with the 14.4% EBIT margin slightly shy of estimates (co...

Free Trial

February 9, 2024 February 9, 2024 1 EN

DnB Markets

ALK-Abello (Buy, TP: DKK127.00) - Looking for continued tablet growth

We expect the focus of the Q4 results to be on ALK showing the rebound in European tablet growth in Q3 was not a one-off, which should further help restore investor confidence. We also expect it to provide guidance suggesting organic growth returning to >10% in 2024 and still-strong margin expansion. However, we believe it is still too early for a strategy update. We reiterate our BUY and have raised our target price to DKK127 (120).

Free Trial

February 2, 2024 February 2, 2024 1 EN

Sandnes Sparebank - Initiation of coverage - The regional challenger

With cNOK29.5bn of lending at end-2023 and a pending merger with Hjelmeland Sparebank, Sandnes Sparebank has secured a strong market position in Rogaland. Supported by positive regional sentiment, distribution of customer dividends and potential capital tailwinds from Basel IV, in addition to still-favourable sector trends, we see scope for solid earnings generation. That said, trading at a 2025e P/E of ~9.0x, we find the valuation fair and initiate coverage with a HOLD and NOK104 target price.

Free Trial

23h 23h 1 EN

Niklas Wetterling

Niklas Wetterling

Wihlborgs (Buy, TP: SEK100.00) - Back up to BUY ahead of Q1

We have upgraded Wihlborgs to BUY (HOLD) and raised our target price to SEK100 (90). We no longer see a near-term risk to the stock from material asset write-downs, but rather expect investors to focus on healthy momentum in lettings at Wihlborgs. With a positive outlook for Q1, we forecast strong net lettings, and are 3% above Infront consensus on profit from property management (PFPM). The results are due at 07:30 CET on 23 April.

Free Trial

23h 23h 1 EN

Johannes Grunselius

Johannes Grunselius

Norske Skog (Buy, TP: NOK54.00) - Moving in the right direction

Due to a less-positive view on prices in combination with a more cautious view on the ramp-up of Norske Skog’s conversion investments in packaging, we have yet again made hefty negative revisions to our 2024–2025e. Still, we believe the long-term transformational case in Norske Skog remains intact while the balance sheet is robust. On a positive side, we note that test liner prices in continental Europe are up c10% in April after being under pressure for six quarters. Still, reflecting our significantly lowered estimates, we have cut our target price to NOK54 (60) but reiterate our BUY.

Free Trial

April 15, 2024 April 15, 2024 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

ALK-Abello (Hold, TP: DKK2050.00) - Strong underlying growth outlook

Alk-Abello A S: 1 director

ALK-Abello (Buy, TP: DKK140.00) - Q3 rebound was not a one-off

ALK-Abello (Buy, TP: DKK127.00) - Looking for continued tablet growth

Sandnes Sparebank - Initiation of coverage - The regional challenger

Wihlborgs (Buy, TP: SEK100.00) - Back up to BUY ahead of Q1

Norske Skog (Buy, TP: NOK54.00) - Moving in the right direction

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe